BriaCell to Present Clinical Data at 2020 American Society of Clinical Oncology (ASCO) Annual Meeting May 29
BERKELEY, Calif. and VANCOUVER, British Columbia, March 31, 2020 (GLOBE NEWSWIRE) — BriaCell Therapeutics Corp. (“BriaCell” or the “Company”) (TSX-V:BCT) (OTCQB:BCTXF), a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, announces that it has been selected to present at the 2020 ASCO Annual Meeting, a virtual event held during the dates of the originally planned in-person Annual Meeting (May 29-June 2, 2020). The ASCO Annual Meeting represents the world’s largest gathering of oncology physicians, biotechnology executives, researchers, and investment analysts to discuss cutting-edge clinical research and therapeutics in oncology.
Dr. Bill Williams, BriaCell’s President & CEO, and Dr. Charles Wiseman, BriaCell’s Scientific Founder and Director, will present clinical data and pathological findings from the Phase I/IIa studies of Bria-IMT™ alone or in combination with checkpoint inhibitors in advanced breast cancer patients.The details of BriaCell’s ASCO poster are as follows:Abstract Title: Breast cancer grade and clinical benefit in patients with advanced breast cancer treated with an engineered whole tumor cell-targeted immunotherapy alone or in combination with checkpoint inhibition.
Session Title: Developmental Therapeutics—Immunotherapy
Session Type: Poster Session
Date: Friday, May 29, 2020
Time: 8:00 AM – 11:00 AM CST
Location: Virtual meeting
Temporary Abstract Submission ID: 306433
Abstract Number for Publication: 3033
Poster Board #: 97
Role Responsibilities: Presenter
Primary Track: Developmental Therapeutics—Immunotherapy Following the presentation, a copy of the poster will be posted on https://briacell.com/novel-technology/scientific-publications/.“We are excited to be invited to present data on BriaCell’s lead candidate, Bria-IMT™. We believe that Bria-IMT™ has a unique mechanism of action that allows it to work with various immunotherapies, including checkpoint inhibitors, to improve the body’s anti-tumor response and potentially offer clinical benefits in patients with advanced breast cancer,” said Dr. Williams.
About American Society of Clinical Oncology (ASCO) ConferenceFounded in 1964, ASCO is the world’s leading professional organization for physicians, oncology professionals, and research scientists in the field of oncology. ASCO’s Mission over the years has been to conquering cancer through research, education, and promotion of the highest quality patient care.ASCO’s Annual meeting represents the world’s largest gathering of oncology physicians, biotechnology executives, researchers, patient advocates, and investment analysts to discuss cutting-edge clinical research and therapeutics in oncology, and to gain insights for improving cancer care.For additional information on the 2020 ASCO’s Annual meeting, please visit https://www.asco.org/.About BriaCellBriaCell is an immuno-oncology focused biotechnology company developing targeted and effective approaches for the management of cancer.For additional information on BriaCell, please visit: https://briacell.com/.Cautionary Note Regarding Forward-Looking InformationExcept for the statements of historical fact, this news release contains “forward-looking information” within the meaning of the applicable Canadian securities legislation (also known as “forward-looking statements”) which are subject to known and unknown risks relevant to the Company in particular and to the biotechnology and pharmaceutical industries in general, uncertainties and other factors that may cause actual events to differ materially from current expectation. These risks are more fully described in the Company’s public filings available at www.sedar.com.These forward-looking statements include, but are not limited to, BriaCell’s plans, objectives, expectations and intentions. Such forward-looking statements reflect BriaCell’s current beliefs and are based on information currently available to management. Although the forward-looking statements contained in this news release are based upon what BriaCell believes are reasonable assumptions, there can be no assurance that actual results will be consistent with these forward-looking statements.Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The Company disclaims any intention or obligation, except to the extent required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.Contact InformationFor further information, please contact:
BriaCell Therapeutics Corp.:
Manager, Corporate Development